Scholarlink

Introduction <p>This study aimed to examine glucose metrics and insulin delivery patterns in children, adolescents, and adults with type&#xa0;1 (T1D) or 2 (T2D) diabetes in France using the tubeless Omnipod DASH<sup>®</sup> pump with and a continuous glucose monitoring (CGM) sensor connected to myDiabby Healthcare<sup>®</sup> Data Management Platform (DMP).</p> Methods <p>Time-stamped CGM and insulin data were extracted from the DMP on December 6, 2023 for 17,344 users whose first data point from the tubeless pump occurred after January 1, 2020. The study population included users with sufficient pump and CGM data (≥ 90&#xa0;days of use) and ≥ 15.5% of CGM use days reaching &gt; 70% coverage. Analyses were performed by type of diabetes and age group.</p> Results <p>Among 14,757 users included in this analysis, most reported having T1D (93.7%), the median age was 33&#xa0;years (Q1–Q3, 16–51), and the median duration of pump use was 545&#xa0;days for people with T1D and 505&#xa0;days for people with T2D (1.49 and 1.38&#xa0;years, respectively). People with T1D spent a median of 52.5% (Q1–Q3, 43.4–62.5) of time in range (70–180&#xa0;mg/dL, TIR) and a TIR ≥ 70% was attained by 12.6% of users. The median time below range (TBR, &lt; 70&#xa0;mg/dL) was 3.7% (Q1–Q3, 2.1–6.1). For users with T2D, median TIR was 66.9% (Q1–Q3, 54.0–77.8), with 42.8% of users achieving a TIR ≥ 70%. Over 90% of all users consumed less than 60&#xa0;UI/day.</p> Conclusion <p>This robust and scalable analysis of a database of substantial quantity, density, and quality found that tubeless pump users achieved moderate glycemic outcomes overall with favorablesafety outcomes in particular, and used the pump consistently. Such databases could be useful for research and patient care, and further work will show how best to use them.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tubeless Insulin Pump Combined with a Cloud-Based Data Management Platform: Real-World Evidence from 14,765 French People with Diabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月1日

查看全文
  • Nathalie Jeandidier,
  • Arthur Bagel,
  • Alice Bonin,
  • Gabriel Guigand,
  • Bruno Guerci

摘要

Introduction

This study aimed to examine glucose metrics and insulin delivery patterns in children, adolescents, and adults with type 1 (T1D) or 2 (T2D) diabetes in France using the tubeless Omnipod DASH® pump with and a continuous glucose monitoring (CGM) sensor connected to myDiabby Healthcare® Data Management Platform (DMP).

Methods

Time-stamped CGM and insulin data were extracted from the DMP on December 6, 2023 for 17,344 users whose first data point from the tubeless pump occurred after January 1, 2020. The study population included users with sufficient pump and CGM data (≥ 90 days of use) and ≥ 15.5% of CGM use days reaching > 70% coverage. Analyses were performed by type of diabetes and age group.

Results

Among 14,757 users included in this analysis, most reported having T1D (93.7%), the median age was 33 years (Q1–Q3, 16–51), and the median duration of pump use was 545 days for people with T1D and 505 days for people with T2D (1.49 and 1.38 years, respectively). People with T1D spent a median of 52.5% (Q1–Q3, 43.4–62.5) of time in range (70–180 mg/dL, TIR) and a TIR ≥ 70% was attained by 12.6% of users. The median time below range (TBR, < 70 mg/dL) was 3.7% (Q1–Q3, 2.1–6.1). For users with T2D, median TIR was 66.9% (Q1–Q3, 54.0–77.8), with 42.8% of users achieving a TIR ≥ 70%. Over 90% of all users consumed less than 60 UI/day.

Conclusion

This robust and scalable analysis of a database of substantial quantity, density, and quality found that tubeless pump users achieved moderate glycemic outcomes overall with favorablesafety outcomes in particular, and used the pump consistently. Such databases could be useful for research and patient care, and further work will show how best to use them.